Ann Kessler - Epigenomics AG Insider

Member of the Supervisory Board

Dr. Ann Clare Kessler, Ph.D. is Vice Chairwoman of the Supervisory Board of Epigenomics AG since May 2, 2012. She was Member of the Supervisory Board since June 28, 2005. For more than 30 years, she held several senior positions at HoffmannLa Roche Inc. in the United States, including Vice President and Head of Exploratory Research and Vice President of Pharmacology and Chemotherapy, prior to moving to Switzerland where she was in charge of the International Project Management group of HoffmannLa Roche in Basel for another five years until 1995. She serves on the Board of Directors of MedGenesis Therapeutix, Inc., among others. She holds a BS degree in Biology, which she gained from College of Notre Dame in 1965 a MS degree in Biochemistry, which she obtained from North West London University in 1967 as well as a Doctorate in Philosophy degree in Biochemistry, which she earned from New York University in 1973.
  Executive Since 2012      
49 30 243 450  http://www.epigenomics.de

Management Efficiency

The company has return on total asset (ROA) of (25.16) % which means that it has lost $25.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (70.57) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Zongxian CaiCathay Financial Holding Co Ltd
2014
Daqing HongCathay Financial Holding Co Ltd
2013
ChihFong WangCathay Financial Holding Co Ltd
2014
PoTsang HsiehCathay Financial Holding Co Ltd
2013
JianHsing WuCathay Financial Holding Co Ltd
2016
Jun ChoiSK Innovation
2014
Chongyi DengCathay Financial Holding Co Ltd
2013
JeanFrancois GuilleminBouygues SA
1998
Xilin HeCathay Financial Holding Co Ltd
N/A
Jang SeoSK Innovation
N/A
TzungHan TsaiCathay Financial Holding Co Ltd
2011
ChiaSheng ChangCathay Financial Holding Co Ltd
2015
Zonghan CaiCathay Financial Holding Co Ltd
2011
Nyoman MastraPT AKR Corporindo Tbk
2009
Sabirin SaimanPT AKR Corporindo Tbk
1994
Francis PengCathay Financial Holding Co Ltd
2016
Zhifeng WangCathay Financial Holding Co Ltd
2014
Deyan WengCathay Financial Holding Co Ltd
N/A
YuChin ChengCathay Financial Holding Co Ltd
2015
Shuguang ZhangCathay Financial Holding Co Ltd
2015
Chaoxiang LinCathay Financial Holding Co Ltd
2015

Entity Summary

Epigenomics AG, a molecular diagnostics company, engages in developing and commercializing a pipeline of proprietary solutions for screening and diagnosis of cancer in Europe, North America, and internationally. Epigenomics AG [EPGNF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Did you try this?

Run Volatility Analysis Now
   

Volatility Analysis

Get historical volatility and risk analysis based on latest market data
Hide  View All  Next  Launch Volatility Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Epigenomics AG to your portfolio

Top Management

Epigenomics AG Leadership Team
Albert Weber, President
Antje Zeise, Executive
Guenther Reiter, Executive
Gregory Hamilton, CEO, MBA
Ann Kessler, Executive
Heino Prondzynski, Chairman
Thomas Taapken, CFO
Annett Dietrich, Executive
Noel Doheny, CEO
Nicola HennebergBusse, President
Uwe Staub, President, Ph.D
Peter Vogt, Executive

Stock Performance

Epigenomics AG Performance Indicators